An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

This study is testing TCC1727 — a new experimental drug — in combination with other cancer treatments in adults with advanced or metastatic solid tumors, including lung cancer, endometrial cancer, colorectal cancer, bladder cancer, and stomach cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with an advanced solid tumor that has progressed despite standard treatments, or for which no standard treatment is available - Your specific cancer type may qualify depending on which treatment combination group you are enrolled in (e.g., lung cancer, endometrial cancer, gastric cancer, etc.) - You are in acceptable physical condition and your organs function within required limits **You may NOT be eligible if...** - You have active brain metastases causing symptoms - You have a serious autoimmune disease requiring systemic treatment - You have HIV, active hepatitis B or C, or active tuberculosis - You have had a stem cell or organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.